Design of enzyme decorated mucopermeating nanocarriers for eradication of H. pylori infection

Zafar, Hajra; Kiani, Maria Hassan; Raza, Faisal; Rauf, Aisha; Chaudhery, Iqra; Ahmad, Nasir M.; Akhtar, Sohail; Shahnaz, Gul

doi:10.1007/s11051-019-4719-7

Cited by 16 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pereira de Sousa et al [ 232 ] utilized both papain and bromelain as mucolytic enzymes on nanoparticles and found that bromelain-decorated nanoparticles enabled a 4.8-fold increase in permeability compared to papain-decorated nanoparticles. Zafar et al [ 233 ] decorated polycarbophil nanoparticles with papain for amoxicillin delivery, and found a ~ fivefold increase in deep penetration (34 mm) of GI mucus ex vivo when compared to non-decorated nanoparticles. Efiana et al [ 234 ] modified self-emulsifying drug delivery systems (SEDDS) with 0.5% papain-palmitate and found a threefold increase in mucus permeability when compared to unmodified SEDDS.…”

Section: Active Mucus-penetrating Systems: Mucolysismentioning

confidence: 99%

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

2022

View full text Add to dashboard Cite

Oral delivery of therapeutics is the preferred route of administration due to ease of administration which is associated with greater patient medication adherence. One major barrier to oral delivery and intestinal absorption is rapid clearance of the drug and the drug delivery system from the gastrointestinal (GI) tract. To address this issue, researchers have investigated using GI mucus to help maximize the pharmacokinetics of the therapeutic; while mucus can act as a barrier to effective oral delivery, it can also be used as an anchoring mechanism to improve intestinal residence. Nano-drug delivery systems that use materials which can interact with the mucus layers in the GI tract can enable longer residence time, improving the efficacy of oral drug delivery. This review examines the properties and function of mucus in the GI tract, as well as diseases that alter mucus. Three broad classes of mucus-interacting systems are discussed: mucoadhesive, mucus-penetrating, and mucolytic drug delivery systems. For each class of system, the basis for mucus interaction is presented, and examples of materials that inform the development of these systems are discussed and reviewed. Finally, a list of FDA-approved mucoadhesive, mucus-penetrating, and mucolytic drug delivery systems is reviewed. In summary, this review highlights the progress made in developing mucus-interacting systems, both at a research-scale and commercial-scale level, and describes the theoretical basis for each type of system.

show abstract

Section: Active Mucus-penetrating Systems: Mucolysismentioning

confidence: 99%

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

2022

View full text Add to dashboard Cite

show abstract

“…Charge on the surface of biomimetic nanoparticles is important because surface charges can alter the vital properties of nanoparticles. [ 63 ] For example, nanoparticles with a positive charge are more prone to systemic toxicity and are rapidly eliminated from circulation. Whereas negatively charged nanoparticles have prolonged circulation time with lower systemic toxicity.…”

Section: Design Parameters Of Biomimetic Nanotechnology For Efficientmentioning

confidence: 99%

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Raza

Zafar

Zhang

et al. 2021

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Immunotherapy will significantly impact the standard of care in cancer treatment. Recent advances in nanotechnology can improve the efficacy of cancer immunotherapy. However, concerns regarding efficiency of cancer nanomedicine, complex tumor microenvironment, patient heterogeneity, and systemic immunotoxicity drive interest in more novel approaches to be developed. For this purpose, biomimetic nanoparticles are developed to make innovative changes in the delivery and biodistribution of immunotherapeutics. Biomimetic nanoparticles have several advantages that can advance the clinical efficacy of cancer immunotherapy. Thus there is a greater push toward the utilization of biomimetic nanotechnology for developing effective cancer immunotherapeutics that demonstrate increased specificity and potency. The recent works and state‐of‐the‐art strategies for anti‐tumor immunotherapeutics are highlighted here, and particular emphasis has been given to the applications of cell‐derived biomimetic nanotechnology for cancer immunotherapy.

show abstract

“…In view of the high morbidity and mortality of GC, the study on the etiology of GC has attracted many scholars. Studies have shown that obesity, gastroesophageal reflux, unreasonable diet, Helicobacter pylori infection, and atrophic gastritis are all high-risk factors for GC [2][3][4]. At present, surgical resection of the tumor is still the main method for the treatment of GC in clinical practice [5].…”

Section: Introductionmentioning

confidence: 99%

The Effect and Mechanism of lncRNA NR2F1-As1/miR-493-5p/MAP3K2 Axis in the Progression of Gastric Cancer

Liao¹,

Wen

Luo

2021

Journal of Oncology

View full text Add to dashboard Cite

Background. LncRNA NR2F1-AS1 has been identified as an oncogene in some human tumors, such as breast cancer, nonsmall cell lung cancer, and esophageal squamous cell carcinoma. Nonetheless, whether NR2F1-AS1 is involved in the progression of gastric cancer (GC) remains unknown. Methods. The expression patterns of NR2F1-AS1, MAP3K2, and miR-493-5p in GC tissues and cells were detected by RT-qPCR. The protein expression of MAP3K2 was assessed by the Western blotting assay. The MTT assay and flow cytometry were performed to measure cell proliferation and cell apoptosis in GC cells. The transwell assay was adopted to assess cell migration in GC cells. The relationship between NR2F1-AS1, MAP3K2, and miR-493-5p was verified by a dual-luciferase reporter assay. Results. The increased NR2F1-AS1 and MAP3K2 expressions were discovered in GC tissues and cells compared with control groups. Knockdown of NR2F1-AS1 and MAP3K2 dramatically suppressed cell proliferation and migration, while it enhanced cell apoptosis in GC cells. In addition, NR2F1-AS1 was found to be a sponge of miR-493-5p, and MAP3K2 was a downstream gene of miR-493-5p. Moreover, the expression of MAP3K2 was notably reduced by miR-493-5p, and NR2F1-AS1 counteracted the inhibition of miR-493-5p. Conclusion. Thus, NR2F1-AS1 was verified to regulate GC cell progression by sponging miR-493-5p to upregulate MAP3K2 expression.

show abstract

Design of enzyme decorated mucopermeating nanocarriers for eradication of H. pylori infection

Cited by 16 publications

References 43 publications

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

The Effect and Mechanism of lncRNA NR2F1-As1/miR-493-5p/MAP3K2 Axis in the Progression of Gastric Cancer

Contact Info

Product

Resources

About